Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about $64,000 a year.
Neurocrine Biosciences’ New Drug May Cost Patients Taking Recommended Dose Twice As Much As Expected
MarketWatch.com - Top Stories, MarketWatch
Wed, 04/26/2017 - 2:27pm
BING NEWS:
- Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy ...
05/16/2024 - 9:37 am | View Link - Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug
A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to continue marketing a high dose of a pricey cancer treatment.
05/15/2024 - 2:57 am | View Link - More Is Not Always Better: Outdated Drug Dose Strategy in Breast Cancer
Dosage recommendations on drug labels are still typically based on the maximum tolerated dose from phase 1 testing, a holdover from when chemotherapy was about the only thing medical oncologists had ...
05/8/2024 - 1:00 pm | View Link - FDA targets cancer drugs to be less toxic, more cost effective
FDA urges drug companies to reassess cancer drug dosages for maximum impact and fewer side effects, following study on lung cancer drug ...
05/6/2024 - 3:20 am | View Link - CORRECTED-UPDATE 2-US FDA approves Neurocrine Biosciences' movement disorder drug (April 30)
(In April 30 story, corrects headline to say it was Neurocrine's movement disorder drug, not Huntington's disease drug, and removes reference to chorea in paragraph 3) By Sruthi Narasimha Chari ...
05/1/2024 - 7:32 pm | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more